Findings from a previous report also correlated epigenetic age acceleration difference measures in ALS/FTD patients with C9orf72 mutations with a more severe disease phenotype as represented by shorter disease duration and earlier age of onset primarily in the blood, and to an extent, with an earlier age of onset in brain tissues [18]. The gene discussed is C9orf72; the disease is frontotemporal dementia.